Characteristics of 29 previously untreated AML patients from whom primary-cell samples were obtained for efflux studies
. | No. . | % . |
|---|---|---|
| Sex | ||
| Female | 16 | 55 |
| Male | 13 | 45 |
| Race | ||
| Asian, non-Hispanic | 1 | 3 |
| Black, non-Hispanic | 3 | 10 |
| White, non-Hispanic | 25 | 86 |
| FAB class | ||
| M0 | 3 | 10 |
| M1 | 4 | 14 |
| M2 | 13 | 45 |
| M4 | 6 | 21 |
| M5 | 3 | 10 |
| AML onset | ||
| De novo | 16 | 55 |
| Secondary | 5 | 17 |
| Unknown | 8 | 27 |
| Evaluable cytogenetics | 24 | 83 |
| Normal karyotype | ||
| Yes | 10 | 42 |
| No | 14 | 58 |
| Specific abnormalities | ||
| 5-/5q- | 1 | 4 |
| inv(16) | 3 | 13 |
| t(8;21) | 1 | 4 |
| 8+ | 2 | 8 |
| Other abnormality | 7 | 29 |
. | No. . | % . |
|---|---|---|
| Sex | ||
| Female | 16 | 55 |
| Male | 13 | 45 |
| Race | ||
| Asian, non-Hispanic | 1 | 3 |
| Black, non-Hispanic | 3 | 10 |
| White, non-Hispanic | 25 | 86 |
| FAB class | ||
| M0 | 3 | 10 |
| M1 | 4 | 14 |
| M2 | 13 | 45 |
| M4 | 6 | 21 |
| M5 | 3 | 10 |
| AML onset | ||
| De novo | 16 | 55 |
| Secondary | 5 | 17 |
| Unknown | 8 | 27 |
| Evaluable cytogenetics | 24 | 83 |
| Normal karyotype | ||
| Yes | 10 | 42 |
| No | 14 | 58 |
| Specific abnormalities | ||
| 5-/5q- | 1 | 4 |
| inv(16) | 3 | 13 |
| t(8;21) | 1 | 4 |
| 8+ | 2 | 8 |
| Other abnormality | 7 | 29 |